Related Experiment Video
Updated: Jul 15, 2026

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
Basal cell carcinoma: treatment with imiquimod
M P Bukhardt Pérez1, Ricardo Ruiz-Villaverde, M J Naranjo Díaz
1Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain.
Background:
Basal cell carcinoma (BCC) is the most common cutaneous malignancy. There are various approaches to its treatment, but imiquimod, the immune response modifier, offers a topical, noninvasive, nonsurgical therapeutic option.
Methods:
We present our experience of the treatment of 96 patients with BCCs during the period March 2002 to February 2004 at the Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain. One hundred and forty-one tumors (nodular, superficial, and pearly/ulcerated clinical types) were treated with imiquimod.
Results:
The clinical cure rate at 12 months was 80-85%.
Conclusion:
Our experience indicates that imiquimod is a reasonable option for the treatment of BCC. It is low cost, can be delivered via ambulatory care, and has tolerable side-effects.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Clinical Applications of Epidermal Stem Cells
Targeted Cancer Therapies
There are several types of targeted therapies against specific...